肿瘤标志物在肺癌联合诊断的临床应用探讨

Study on Clinical Application of Tumor Markers in the Lung Cancer Combined Diagnosis

目的研究分析肿瘤标志物在肺癌联合诊断的临床应用探讨。方法方便选取2016年10月—2017年10月该院收治的60例肺癌患者为研究对象,对照组患者为60名健康体检人员,分析肿瘤标志物与肺癌病例类型分布关系,详细记录患者相关临床指标。结果实验组CEA水平为(56.78±6.54)μg/L,对照组CEA水平为(4.32±1.43)μg/L,差异有统计学意义(t=4.55,P<0.05)。实验组与对照组患者的CF211水平分别为(6.78±1.12)mg/L与(1.16±0.45)mg/L,差异有统计学意义(t=5.77,P<0.05)。实验组NSE水平为(33.12±4.32)μg/L,对照组NSE水平为(10.09±1.43)μg/L,差异有统计学意义(t=8.76,P<0.05)。腺癌CF211水平为(6.60±1.20)mg/L,CEA水平为(69.33±20.12)μg/L,与小细胞癌相比差异有统计学意义(t=6.89,P<0.05)。实验组CF211异常率为40.00%,CEA异常率为53.33%,NSE异常率为33.33%。结论肿瘤标志物在肺癌联合诊断中具有重要临床价值,能够准确诊断肺癌,准确率较高,具有临床推广的意义。

Objective To research and analyze the clinical application of tumor markers in the lung cancer combined diagnosis. Methods 60 cases of patients with lung cancer admitted and treated in our hospital from October 2016 to October2017 were selected, and 60 cases of healthy physical examination people were selected as the control group, and the correlation between the tumor markers and lung cancer type was analyzed, and the related clinical indicators of patients were recorded in detail. Results The CEA level in the experimental group and in the control group was respectively（56.78±6.54）μg/L and（4.32±1.43）μg/L, and the difference was statistically significant（t=4.55, P0.05）, and the CF211 level in the experimental group and in the control group was respectively（6.78 ±1.12）mg/L,（1.16 ±0.45）mg/L, and the difference was statistically significant（t=5.77, P0.05）, and the NSE level in the experimental group and in the control group was respectively（33.12±4.32）μg/L and（10.09±1.43）μg/L, and the difference was statistically significant（t=8.76, P0.05）, and the adenocarcinoma CF211 level and CEA level were respectively（6.60±1.20）mg/L and（69.33±20.12）μg/L, and the differences were statistically significant compared with the small cell cancer（t=6.89, P 0.05）, and the CF211 abnormal rate, CEA abnormal rate and NSE abnormal rate in the experimental group were respectively 40.00%, 53.33% and 33.33%. Conclusion The clinical value of tumor markers in the lung cancer combined diagnosis is important, which can accurately diagnose the lung cancer with higher accurate rate and clinical promotion value.